Canada - English
Canada - Français
For a refined risk estimateof local recurrence
Primary study group results were presented at ASCO 2018.
Help Stage II colon cancer patients understand the power of genomics
In a large clinical data setGPS increased AS utilzation
Nuclear-specific vs. nuclear-agnostic AR-V7 testing
Your Oncotype DX score can help you decide.
Oncotype DX has helped thousands of women find out.
When Dan's Colon Recurrence Score came back low, he decided against chemotherapy.
Read what the Wall Street Journal is saying about the Oncotype DX Genomic Prostate Score test.
on the utility of genomics in early breast cancer
Updated NCCN Guidelines® from the National Comprehensive Cancer Network® (NCCN®) underscore the unique advantage of the 21-gene (Oncotype DX) test as the only preferred multi-gene test to determine chemotherapy benefit for patients with node-negative early-stage breast cancer. (See page BINV-6 in the Guidelines.)
Additionally, the NCCN Guidelines elevated multi-gene assays, including the 21-gene (Oncotype DX) test into the algorithm to consider for assessing prognosis and determining chemotherapy benefit for patients with micrometastases and 1–3 positive nodes. (See page BINV-7 in the Guidelines.)
Read the official press release on the significance of these updated guidelines.
The landmark TAILORx trial results provide definitive answers
Have a specific question? Want to keep up with our latest news? We're here for you.